$PGEN

Free money by Wednesday 5th of August - $PGEN

Precigen's recently FDA-approved RRP vaccine (Papzimeos) launched in Q4 2025 and showed strong Q1 2026 results. Q2 2026 earnings release on August 5th—a week early—coincides with newly assigned J-code reimbursement status, which should expand patient access and drive revenue growth. The stock has broken above key technical levels (20-day SMA, tested 50-day SMA) and recently hit 52-week highs, suggesting traders are underestimating the catalysts.